Expert Ratings For Intra-Cellular Therapies
Expert Ratings For Intra-Cellular Therapies
關於細胞內療法的專家評級
A comprehensive examination of how financial...In the latest quarter, 16 analysts provided ratings for Intra-Cellular Therapies (NASDAQ:ITCI), showcasing a mix of bullish and bearish perspectives.
在最新的一個季度，有16位分析師對Intra-Cellular Therapies (納斯達克：ITCI)進行了評級，展示了看好和看淡的觀點。
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
以下表格概括了他們最近的評級，展示了過去30天內的情緒演變並與之前的幾個月進行了比較。
In the assessment of 12-month price targets, analysts unveil insights for Intra-Cellular Therapies, presenting an average target of $97.06, a high estimate of $130.00, and a low estimate of $74.00. Marking an increase of 3.26%, the current average surpasses the previous average price target of $94.00.
In the assessment of 12-month price targets, analysts unveil insights for Intra-Cellular Therapies, presenting an average target of $97.06, a high estimate of $130.00, and a low estimate of $74.00. Marking an increase of 3.26%, the current average surpasses the previous average price target of $94.00.
Investigating Analyst Ratings: An Elaborate Study
分析師評級的調查：一項詳盡的研究
A comprehensive examination of how financial...
對於Intr...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。